Innova Captab Ltd (Pharma - API) — fundamental analysis, earnings data, and key metrics. PE: 29.0. ROE: 14.3%. This stock is not currently in the Nifty 500 momentum outperformers list.
Deep value thesis based on recent earnings • Updated Mar 21, 2026
Innova Captab is transitioning from a struggling pharma player to a high-growth CDMO and Branded Generics business with revenue surging 42.3% YoY in Q3 FY26, driven by facility ramp-ups and regulatory approvals that are finally translating to margin stability.
Verdict
TURNAROUND_IN_PROGRESS
Re-rating catalysts over the next 2-4 quarters • Updated Mar 21, 2026
Management guidance indicates Jammu facility will contribute positively to profits next year, adding ₹15-20 Cr quarterly PAT.
Impact: +₹15 Cr revenue
“Jammu facility revenue jumped to ₹89 Cr in Q3 (from ₹60 Cr last quarter) with UK-MHRA and PIC/s certifications enabling export growth.”
New US/EU contracts from recent certifications expected to extend order book from current 12 months.
Impact: +₹25 Cr revenue
“CDMO business generated ₹298.7 Cr in Q3 FY26, up 29% YoY from ₹231.6 Cr with exports forming 35% of Q3 revenue mix.”
Potential first meaningful payout since FY23, signaling confidence in cash flow sustainability.
“Board met on Jan 23, 2026 to review Q3 results and consider interim dividend.”
Risks that could prevent re-rating or deepen the value trap
If receivables days exceed 110
Impact: -300 bps margin impact
Management view: Management acknowledged working capital challenges but expects improvement with Jammu facility profitability.
Monitor: Receivables days
If pledge increases further
Management view: No official comment on reducing pledge levels.
Monitor: Promoter pledge percentage
If API prices fall 15%+ in key markets
Impact: -400 bps margin impact
Management view: Management is hedging exposure through long-term contracts with key customers.
Monitor: API price index
Forward-looking targets from management for FY27
Revenue Growth Target
25%
Implied PAT Growth
30%
OPM Guidance
16.5%
Capex Plan
₹50 Cr
Credit Growth Target
20%
NIM Guidance
0%
Key Milestones
• Jammu facility EBITDA positive by Q1 FY27
• CDMO order book to 18 months by Q3 FY27
• Interim dividend in Q4 FY26
The above analysis is AI-generated from publicly available financial data. This is educational research only — not investment advice. Last updated Mar 21, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Innova Captab Ltd's latest quarterly results (Dec 2025) show
Innova Captab Ltd's current PE ratio is 29.0x.
Innova Captab Ltd's price-to-book ratio is 3.8x.
Innova Captab Ltd's fundamental strength based on key financial ratios
Innova Captab Ltd has a debt-to-equity ratio of N/A.
Innova Captab Ltd's return ratios over recent years
Innova Captab Ltd's operating cash flow is positive (FY2025).
Innova Captab Ltd's current dividend yield is 0.30%.
Innova Captab Ltd's shareholding pattern (Dec 2025)
Innova Captab Ltd's promoter holding has remained stable recently.
Innova Captab Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Innova Captab Ltd has 3 key growth catalysts identified from recent earnings analysis
Innova Captab Ltd has 3 key risks worth monitoring
Innova Captab Ltd's management has provided the following forward guidance for FY27
Based on quantitative research signals, here is why Innova Captab Ltd may be worth studying
Innova Captab Ltd investment thesis summary:
Innova Captab Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
